Hyperthyroidism and pulmonary hypertension: An important association

American Journal of the Medical Sciences

Volumn 342, Issue 6, 2011, Pages 507-512

  Vallabhajosula, Sailaja ^a   Radhi, Saba ^a   Cevik, Cihan ^b,c   Alalawi, Raed ^a   Raj, Rishi ^a   Nugent, Kenneth ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER SCHOOL OF MEDICINE   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c ST LUKE S EPISCOPAL HOSPITAL   (United States)

Author keywords

Graves' disease; Hyperthyroidism; Pulmonary hypertension

Indexed keywords

ANTITHYROID AGENT; CALCIUM CHANNEL BLOCKING AGENT; ENDOTHELIN; ENDOTHELIN 1; ENDOTHELIN RECEPTOR ANTAGONIST; INTERLEUKIN 6; PHOSPHODIESTERASE V INHIBITOR; PROSTACYCLIN; RADIOACTIVE IODINE; THALIDOMIDE; THIAMAZOLE; THYROID HORMONE; VASCULOTROPIN;

AGE; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE REGULATION; COST CONTROL; DISEASE ASSOCIATION; DYSPNEA; GOITER; HEALTH CARE COST; HORMONE SUBSTITUTION; HUMAN; HYPERTHYROIDISM; LUNG ARTERY PRESSURE; LUNG BLOOD FLOW; MOLECULAR PATHOLOGY; NONHUMAN; PATHOPHYSIOLOGY; PULMONARY HYPERTENSION; SCREENING TEST; SYSTOLIC BLOOD PRESSURE; THYROID DISEASE; THYROID SURGERY; VASOCONSTRICTION;

EID: 82355183540     PISSN: 00029629     EISSN: 15382990     Source Type: Journal    
DOI: 10.1097/MAJ.0b013e31821790f4     Document Type: Article

References (59)

1. Farber HW, Loscalzo J. Pulmonary arterial hypertension. N Engl J Med 2004;351:16553-65.
2. Badesch DB, Raskob GE, Elliott CG, et al. Pultamonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest 2010;137:376-87.
3. Klein I, Danzi S. Thyroid disease and the heart. Circulation 2007;116: 1725-35. (Pubitemid 47537847)
4. Virani SS, Mendoza CE, Ferreira AC, et al. Grave's disease and pulmonary hypertension: report of 2 cases. Tex Heart Inst J 2003;30: 314-5. (Pubitemid 37499755)
5. Thurnheer R, Jenni R, Russi EW, et al. Hyperthyroidism and pulmonary hypertension. J Intern Med 1997;24:185-8.
6. Marvisi M, Zambrelli P, Brianti M, et al. Pulmonary hypertension is frequent in hyperthyroidism and normalizes after therapy. Eur J Intern Med 2006;17:267-71.v (Pubitemid 43817516)
7. Ismail HM. Reversible pulmonary hypertension and isolated right-sided heart failure associated with hyperthyroidism. J Gen Intern Med 2007;22:148-50. (Pubitemid 47308782)
8. Lozano HF, Sharma CN. Reversible pulmonary hypertension, tricus-pid regurgitation and right-sided heart failure associated with hyperthy-roidism: case report and review of the literature. Cardiol Rev 2004;12: 299-305. (Pubitemid 39425528)
9. Nakchbandi IA, Wirth JA, Inzucchi SE. Pulmonary hypertension caused by Graves' thyrotoxicosis: normal pulmonary hemodynamics restored by (131) treatment. Chest 1999;116:1483-5. (Pubitemid 29536014)
10. Hegazi MO, El Sayed A, El Ghoussein H. Pulmonary hypertension responding to hyperthyroidism treatment. Respirology 2008;13:923-5.
11. Armigliato M, Paolini R, Aggio S, et al. Hyperthyroidism as a cause of pulmonary arterial hypertension: a prospective study. Angiology 2006;57:600-6. (Pubitemid 44564316)
12. Alcázar R, Rey M, de Sequera P, et al. The reversibility of pulmonary hypertension associated with autoimmune hyperthyroidism. Rev Esp Cardiol 1995;48:142-4.
13. Nduyao L, Pop C, Heim J. Reversible pulmonary hypertension in Basedow's disease. Presse Med 2000;29:2216-8. (Pubitemid 32044049)
14. Agraou B, Tricot O, Strecker A, et al. Hyperthyroidism associated with pulmonary hypertension. Arch Mal Coeur Vaiss 1996;89:765-8. (Pubitemid 26200168)
15. Mozo HG, Fernández González MJ, Salgado BJ, et al. Hyperthy-roidism, jaundice, and pulmonary hypertension. An Med Interna 2001; 18:262-4.
16. Moraza J, Esteban C, Aburto M, et al. Reference figures for pulmonary artery pressures after effective treatment of Graves' disease. Arch Bronconeumol 2003;39:45-7. (Pubitemid 36249395)
17. Soroush-Yari A, Burstein S, Hoo GW, et al. Pulmonary hypertension in men with thyrotoxicosis. Respiration 2005;72:90-4. (Pubitemid 40470285)
18. Polo Romero FJ, Fernández Peláez JM, Gato Diez A, et al. Pulmonary hypertension and hyperthyroidism in a pregnant woman. Med Clin (Barc) 2001;117:276-7.
19. Yazar A, Döven O, Atis S, et al. Systolic pulmonary artery pressure and serum uric acid levels in patients with hyperthyroidism. Arch Med Res 2003;34:35-40. (Pubitemid 36216339)
20. Paran Y, Nimrod A, Goldin Y, et al. Pulmonary hypertension and predominant right heart failure thyrotoxicosis. Resuscitation 2006;69: 339-41. (Pubitemid 44294457)
21. Mercé J, Ferrás S, Oltra C, et al. Cardiovascular abnormalities in hyperthyroidism: a prospective Doppler echocardiographic study. Am J Med 2005;118:126-31. (Pubitemid 40202858)
22. Siu CW, Zhang XH, Yung C, et al. Hemodynamic changes in hyperthyroidism-related pulmonary hypertension: a prospective echo-cardiographic study. J Clin Endocrinol Metab 2007;92:1736-42. (Pubitemid 46997180)
23. Hamagawa K, Yabe T, Hayato K, et al. Severe pulmonary hypertension and congestive heart failure in an elderly patient with Basedow's disease. Nippon Ronen Igakkai Zasshi 2009;46:358-63.
24. Li JH, Stafford RE, Aduen JF, et al. Pulmonary hypertension and thyroid disease. Chest 2007;132:793-7.
25. Chu JW, Kao PN, Faul JL, et al. High prevalence of autoimmune thyroid disease in pulmonary arterial hypertension. Chest 2002;122: 1668-73. (Pubitemid 35366080)
26. Castillo Palma MJ, Garcia Hernandez FJ, Montero Venavides P, et al. Thyroid dysfunction in patients with pulmonary arterial hypertension. A cohort study of 58 patients in Spanish. Med Clin 2009;13: 695-700.
27. Sahin M, Sade LE, Tutuncu NB, et al. Systolic pulmonary artery pressure and echocardiographic measurements in patients with euthy-roid Hashimoto's thyroiditis. J Endocrinol Invest 2009;32:530-2.
28. Ma RC, Cheng AY, So WY, et al. Thyrotoxicosis and pulmonary hypertension. Am J Med 2005;118:927-8.
29. Piquilloud L, Blanc MH, Suvá F, et al. Primary pulmonary hypertension arterial and Basedow disease. Rev Med Suisse Romande 2002; 122:545-7.
30. Wasseem R, Mazen E, Walid SR. Hyperthyroidism: a rare cause of reversible pulmonary hypertension. Am J Med Sci 2006;332:140-1. (Pubitemid 44401236)
31. Dougherty MJ, Craige E. Apathetic hyperthyroidism presenting as tricuspid regurgitation. Chest 1973;63:767-72.
32. Okura H, Takatsu Y. High-output heart failure as a cause of pulmonary hypertension. Intern Med 1994;33:363-5.
33. Guntekin U, Gunes Y, Tunder M, et al. QTc dispersion in hyperthy-roidism and its association with pulmonary hypertension. Pacing Clin Electrophysiol 2009;32:494-9.
34. Iranzo-Vasquez D, Rius-Riu F, Pizarro-Lozano P, et al. Severe tricuspid insufficiency as main manifestation of hyperthyroidism in Spanish. Rev Esp Cardiol 1997;50:65-6.
35. Marvisi M, Brianti M, Marani G, et al. Hyperthyroidism and pulmonary hypertension. Respir Med 2002;96:215-20.
36. Okada M, Okura H, Abe Y, et al. Pulmonary hypertension associated with refractory hyperthyroidism: a case report in Japanese. J Cardiol 2001;37:277-83. (Pubitemid 32521945)
37. Chadha C, Pritzker M, Mariash CN. Effect of epoprostenol on the thyroid gland: enlargement and secretion of thyroid hormone. Endocr Pract 2009;15:116-21.
38. Aird WC. Endothelial cell heterogeneity. Crit Care Med 2003;31: S221-30. (Pubitemid 36458171)
39. Smit JW, Eustatia-Rutten CF, Corssmit EP, et al. Reversible dia-stolic dysfunction after long-term exogenous subclinical hyperthyroid-ism: a randomized placebo controlled trial. J Clin Endocrinol Metab 2005;90:6041-7. (Pubitemid 41606523)
40. Leung CC, Moondra V, Catherwood E, et al. Prevalence and risk factors of pulmonary hypertension in patients with elevated pulmonary venous pressure and preserved ejection fraction. Am J Cardiol 2010; 106:284-6.
41. Thomas MR, McGregor AM, Jewitt DE. Left ventricle filling abnormalities prior to and following treatment of thyrotoxicosis-is diastolic dysfunction implicated in thyrotoxic cardiomyopathy? Eur Heart J 1993;14:662-8. (Pubitemid 23170681)
42. Tuder RM, Chacon M, Alger L, et al. Expression of angiogenesis-related molecules in plexiform lesions in severe pulmonary hypertension: evidence for a process of disordered angiogenesis. J Pathol 2001;195:367-74.
43. Papaioannou AI, Zakynthinos E, Kostikas K, et al. Serum VEGF levels are related to the presence of pulmonary arterial hypertension in systemic sclerosis. BMC Pulm Med 2009;9:18.
44. Luidens M, Mousa S, Davis F, et al. Thyroid hormone and angiogenesis. Vascul Pharmacol 2010;52:142-5.
45. Davis P, Leonard J, Davis F. Mechanisms of nongenomic actions of thyroid hormone. Front Neuroendocrinol 2008;29:211-8. (Pubitemid 351467119)
46. Tokuda H, Kato K, Oiso y, et al. Contrasting effects of triiodothyronine on heat shock protein 27 induction and vascular endothelial growth factor synthesis stimulated by TGF-/3 in osteoblasts. Mol Cell Endocrinol 2003;201:33-8. (Pubitemid 36434279)
47. Tuder RM, Yun HJ. Vascular endothelial growth factor of the lung: friend or foe. Curr Opin Pharmacol 2008;8:255-60.
48. Davis PJ. Cytokines and growth factors and thyroid hormone. Curr Opin Endocrinol Diabetes Obes 2008;15:428.
49. Chu CH, Lee JK, Keng HM, et al. Hyperthyroidism is associated with higher plasma endothelin-1 concentrations. Exp Biol Med (Maywood) 2006;231:1040-3.
50. Steiner MK, Syrkina OL, Kolliputi N, et al. Interleukin-6 overex-pression induces pulmonary hypertension. Circ Res 2009;104:236-44.
51. Davis FB, Mousa SA, O'Connor L, et al. Proangiogenic action of thyroid hormone is fibroblast growth factor-dependent and is initiated at the cell surface. Circ Res 2004;94:1500-6. (Pubitemid 38780323)
52. Fujita M, Shannon JM, Irvin CG, et al. Overexpression of tumor necrosis factor-alpha produces an increase in lung volumes and pulmonary hypertension. Am J Physiol Lung Cell mol Physiol 2001;280: L39-49.
53. Spencer C, Hollowell J, Kazarosyan M. et al. National health and nutrition examination survey III thyroid-stimulating hormone (TSH)-thyroperoxidase antibody relationships demonstrate that TSH upper reference limits may be skewed by occult thyroid dysfunction. J Clin Endocrinol Metab 2007;92:4236-40. (Pubitemid 350074737)
54. Roberts KE, Barst RJ, McElroy JJ, et al. Bone morphogenetic protein receptor 2 mutations in adults and children with idiopathic pulmonary arterial hypertension: association with thyroid disease. Chest 2005;128:618S. (Pubitemid 43054165)
55. Vargas F, Fernandez-Rivas A, Osuna A. Effects of methimazole in the early and established phases of NG-nitro-L-arginine methyl ester hypertension. Eur J Endocrinol 1996;135:506-13. (Pubitemid 26364953)
56. Bauditz J, Lochs H. Angiogenesis and vascular malformations: nti-angiogenic drugs for treatment of gastrointestinal bleeding. World J Gastroenterol 2007;13:5979-84. (Pubitemid 350238263)
57. Guidelines for the diagnosis and treatment of pulmonary hypertension. The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009;30:2493-537.
58. Franklyn JA, Maisonneuve P, Sheppard MC, et al. Mortality after the treatment of hyperthyroidism with radioactive iodine. N Engl J Med 1998;338:712-8. (Pubitemid 28115089)
59. Franklyn JA, Sheppard MC, Maisonneuve P. Thyroid function and mortality in patients treated for hyperthyroidism. JAMA 2006; 294:71-80.